TABLE 1.
Demographics and clinical presentation
| Cases/total (%) or median (IQR) | |
|---|---|
| Male | 75/143 (52.4%) |
| Age (y) | 73 (60‐79) |
| Follow‐up time (mo) | 16.8 (3.6‐41.5) |
| Clinical presentation | |
| FVIII activity, IU/dL | 2.0 (0.0‐6.0) |
| aFVIII titer, BU | 20.5 (7.7‐58.8) |
| Hb, g/dL | 9.2 (7.7‐11.3) |
| Bleeding symptoms a | 49/136 (36.0%) |
| Mild bleeding | 87/136 (64.0%) |
| Severe bleeding | 16/136 (11.8%) |
| ICU admission at diagnosis b | |
| Time until diagnosis (d) | |
| From first symptoms until diagnosis | 22 (8–77) |
| From first medical evaluation until diagnosis | 2 (0–10) |
| Identifiable cause | |
| None | 82/130 (63.1%) |
| Malignancy | 24/130 (18.5%) |
| Solid | 15/130 (11.5%) |
| Hematologic | 9/130 (6.9%) |
| Immune‐related | 13/130 (10.0%) |
| Post‐partum | 6/130 (4.6%) |
| Infection‐related | 3/130 (2.3%) |
| Drug‐induced | 2/130 (1.5%) |
Abbreviations: aFVIII, anti FVIII antibody; BU, Bethesda units; FVIII, factor VIII; ICU, intensive care unit.
a
Based on ISTH criteria.
b
In all cases reason for ICU admission was bleeding related.